Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2022
Date Filed: January 4, 2022
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate governance updates rather than financial performance data.
Material Changes
- Corporate Governance: The company announced the resignation of Non-Executive Directors (detailed in Exhibit 99.1).
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, or risk factors beyond the announcement of director resignations. The document serves primarily to incorporate the resignation announcement by reference into existing Registration Statements (Form S-8 and Form F-3).
Investor Verification Checklist
- Verify the specific identities of the resigning Non-Executive Directors in Exhibit 99.1.
- Confirm the effective date of the resignations and any transition plans for board composition.
- Review the referenced Registration Statements (Files No. 333-251073, 333-248980, 333-228671, 333-251647, 333-249311, 333-231417, and 333-250076) for updated prospectus information.